People usually search for this
Tesamorelin 10mg
$125.00
Products will arrive in a lyophilized (powder) form for maximum stability
Tesamorelin is a modified GHRH(1-44) analog with an N-terminal trans-3-hexenoic acid modification that resists DPP-4 cleavage, supporting once-daily dosing. Clinical research documented reductions in visceral adipose tissue, with FDA approval as Egrifta for HIV-associated lipodystrophy. Supplied as a 10mg lyophilized vial at ≥99% HPLC purity, for research use only.
Volume discounts
Auto-applied at checkout
Free shipping on orders of $200+
Compound Identity
COMPOUND NAME
Tesamorelin
SYNONYMS
TH9507, Egrifta®
CAS NUMBER
218949-48-5
MOLECULAR FORMULA
C221H366N72O61S
MOLECULAR WEIGHT
~5137.9 Da
STRUCTURE
Synthetic 44-amino acid peptide
PEPTIDE SEQUENCE
H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH?
CHEMICAL STRUCTURE
Molecular Formula: C221H366N72O61S
Source: PubChem
Mechanism of Action
Tesamorelin acts as a GHRH receptor agonist. It binds to pituitary somatotroph cells, stimulating the synthesis and release of endogenous GH. This leads to elevated IGF-1, promoting anabolic and lipolytic activity primarily in adipose tissue, particularly reducing VAT with minimal impact on subcutaneous fat.
1
GHRH Receptor (GHRH-R) Agonism
2
Stimulates pulsatile growth hormone (GH) secretion: Tesamorelin binds to GHRH receptors on a pituitary somatotrophs, increasing cyclic AMP (cAMP) levels and activating PKA and MAPK signaling pathways, resulting in physiologic GH release that mimics natural circadian pulsatility2,3.
3
Increases circulating IGF-1 levels: Endogenous GH released in response to tesamorelin upregulates hepatic IGF-1 production, leading to enhanced lipolytic, anabolic, and metabolic activity throughout peripheral tissues1.
4
Preserves feedback sensitivity: Unlike exogenous GH therapy, tesamorelin maintains the hypothalamic-pituitary feedback loop, allowing for regulation of GH and IGF-1 within physiologic ranges3,4.
5
Depot-selective lipolysis: The GH/IGF-1 signaling axis preferentially targets visceral adipose depots, promoting triglyceride hydrolysis and reduced VAT without significantly affecting subcutaneous fat or lean mass1,3.
6
Receptor Binding Affinity: Tesamorelin binds the GHRH receptor with high affinity, exhibiting similar potency to endogenous GHRH (IC?
?, Human = ~0.069 nM) and greater resistance to enzymatic degradation by DPP-IV2,3.
Biological Activity
Tesamorelin increases pulsatile GH and IGF-1 levels, reduces VAT, and improves lipid profiles and body image metrics in HIV patients. It shows minimal effect on glucose homeostasis but may slightly raise HbA1c in some users.
Storage
- −20°C or below. Protect from light and moisture.
Drug Categories
Peptides; Growth Hormone Secretagogues; Endocrine Modulators
Additional Notes
- FDA-approved for HIV-associated lipodystrophy
- Reduces VAT without worsening glycemic control
- Improves hepatic steatosis in HIV-associated NAFLD
Summary Table
Property
Description
CAS Number
218949-48-5
Molecular Formula
C221H366N72O61S
Molecular Weight (MW)
~5137.9 Da
Mechanism of Action
Dual agonist at GIP and GLP-1 receptors; biased signaling, GIPR-dominant
Biological Activity
Reduces VAT, increases IGF-1, minimal impact on glucose control
Supplied Form
Lyophilized powder
Purity
≥99% (HPLC)
Storage
−20°C, dry, light-protected
Drug Categories
Peptides; Incretin mimetic
Additional Notes
FDA-approved; used in HIV-associated lipodystrophy and NAFLD
Disclaimer
For Research Use Only. Not intended for human or veterinary use. This compound is supplied solely for laboratory and R&D purposes.
Detailed Product Description
Tesamorelin is a stabilized synthetic analogue of human growth hormone-releasing hormone (GHRH), comprising a 44-amino acid sequence with an N-terminal modification that enhances resistance to enzymatic degradation. Clinically, Tesamorelin is approved for the treatment of excess abdominal fat in HIV-infected individuals with lipodystrophy. This approval is based on consistent reductions in visceral adipose tissue (VAT) observed across controlled studies. The compound has also been evaluated in metabolic conditions related to HIV, including hepatic steatosis, with emerging evidence suggesting benefit in reducing intrahepatic lipid content and modulating fibrotic progression. Tesamorelin is intended for investigational and clinical use in the context of metabolic disorders characterized by altered fat distribution or growth hormone axis dysregulation. It is not indicated for use in the general population outside approved clinical settings.
Research Highlights
VAT Reduction:
Tesamorelin significantly reduces visceral adipose tissue (~15–20%) in HIV-associated lipodystrophy, with effects maintained over 52 weeks in continuous users.
Fat Selectivity:
Targets VAT with minimal impact on subcutaneous fat or lean mass.
Body Composition Benefits:
Treatment is associated with reductions in waist circumference and improvements in body image-related outcomes.
Liver Effects:
In HIV-associated NAFLD, tesamorelin reduces liver fat and attenuates fibrosis progression, supported by transcriptomic downregulation of fibrotic and inflammatory gene pathways.
Metabolic Profile:
IGF-1 levels rise predictably with treatment; glycemic effects are minimal, with only modest, clinically insignificant increases in HbA1c observed.
Pharmacokinetic Profile
Route of Administration
Subcutaneous
Dosing Frequency
Once daily
- Route of Administration: Subcutaneous injection
- Dosing Frequency: Once daily
- Half-Life: ~38 minutes in HIV+ patients2
- Formulation: Lyophilized acetate salt for reconstitution
Formulation & Handling
- Reconstitute lyophilized powder in sterile bacteriostatic water for injection (0.9% benzyl alcohol)
- Store reconstituted solution at 2–8°C and use within 14 days
- Unreconstituted vials should be stored at −20°C in a dry, light-protected environment
- Avoid repeated freeze-thaw cycles; aliquot as needed for stability
- Stable for up to 12 months when stored properly in lyophilized form
Clinical Trial Activity
Trial ID
Title
Phase
Study Type
Sponsor
NCT02572323
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
2
Interventional
University of California, San Diego
NCT02012556
Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients
1
Interventional
Theratechnologies
NCT02196831
Tesamorelin Effects on Liver Fat and Histology in HIV
N/A
Interventional
Massachusetts General Hospital
NCT06554717
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH)
2
Interventional
Massachusetts General Hospital
References
1
Spooner, L. M., & Olin, J. L. Tesamorelin: A Growth Hormone-Releasing Factor Analogue for HIV-Associated Lipodystrophy. Ann Pharmacother 46, 240–247 (2012).
2
Dhillon, S. Tesamorelin: A review of its use in the management of HIV-associated lipodystrophy. Drugs 71, 1071–1091 (2011).
3
Fourman, L.T., Stanley, T.L., Bhasin, J.M. et al. Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Sci. Rep. 11, 20258 (2021).
4
Wang, Y. & Tomlinson, B. Tesamorelin, a human growth hormone releasing factor analogue. Expert Opin. Investig. Drugs 18, 303–310 (2009).
Quality & Purity
This product is synthesized via solid-phase peptide synthesis (SPPS) and tested to ≥99% purity by HPLC with identity confirmed by mass spectrometry. A Certificate of Analysis (COA) is available for every batch. Learn about our full quality and testing process →
Related Products
Bioregulators
Vesugen 20mg
$70.00
Read more 
Exercise
MOTS-C 40mg
$200.00
Add to cart 
GHRP
Tesamorelin 20mg
$200.00
Add to cart Related products
BPC-157 5mg
Summary Description: BPC-157 is a synthetic pentadecapeptide corresponding to a partial sequence of a protein found in human gastric juice. In preclinical models, it has demonstrated pro-angiogenic, cytoprotective, and anti-inflammatory properties1-3. BPC-157 accelerates tissue repair across tendon, ligament, muscle, and epithelial models by modulating nitric oxide pathways, upregulating VEGF and other growth factors, and promoting fibroblast migration4. Its chemical stability in gastric environments and efficacy across multiple administration routes make it a candidate for further investigation in regenerative pharmacology2.
Products will arrive in a lyophilized (powder) form for maximum stability
BPC-157/TB-500 10+10mg
Summary Description: BPC-157 and TB-500 is an investigational blend of two well-studied peptides known for their regenerative and cytoprotective properties. BPC-157, derived from a gastric protein, is recognized for promoting angiogenesis, cellular migration, and tissue healing across various organ systems1,2. TB-500, a synthetic fragment of thymosin beta-4, enhances cellular motility, reduces inflammation, and stimulates new blood vessel formation3,4. Together, this synergistic blend is being explored in preclinical research for its ability to accelerate wound healing, mitigate inflammation, and enhance recovery in models of soft tissue injury, nerve damage, and musculoskeletal trauma. While individually effective, the co-administration of BPC-157 and TB-500 may produce more robust regenerative outcomes by targeting both the structural and signaling components of tissue repair.
Products will arrive in a lyophilized (powder) form for maximum stability
DSIP 10mg
Summary Description: Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring peptide known for its ability to support deep, restorative sleep and help balance the body’s stress and hormonal responses. Originally discovered in the 1970s from the blood of sleeping animals, DSIP has since been studied for its potential to promote slow-wave (deep) sleep, calm the nervous system, and support recovery. Studies suggest that DSIP works by helping the brain regulate its natural sleep rhythms and hormone balance, making it a promising peptide for overall rest, resilience, and well-being1-4.
Products will arrive in a lyophilized (powder) form for maximum stability
MOTS-C 40mg
Summary Description: MOTS-c (Mitochondrial ORF of the 12S rRNA type c) is a mitochondrial-derived peptide that plays a vital role in regulating metabolism, energy balance, and cellular stress responses. Discovered in 2015, MOTS-c functions as a signaling molecule that helps the body respond to metabolic stress by improving glucose uptake, enhancing insulin sensitivity, and promoting fat metabolism. It acts as a mitochondrial messenger that communicates with the nucleus to maintain cellular homeostasis, making it a promising target for research on metabolic health, exercise performance, and healthy aging1-4.
Products will arrive in a lyophilized (powder) form for maximum stability
Pinealon 20mg
Summary Description: Pinealon is a synthetic tripeptide developed as a neuroprotective and geroprotective agent. It exerts potent antioxidant effects, modulates cellular signaling, and supports cognitive function, cell viability, and adaptation to stress. Pinealon has been extensively studied in animal models for its efficacy in reducing oxidative stress, supporting learning and memory, and modulating key brain neurotransmitter and receptor systems1-4.
Products will arrive in a lyophilized (powder) form for maximum stability
PT-141 10mg
Summary Description: PT-141 is a synthetic cyclic heptapeptide derivative of alpha-melanocyte stimulating hormone (?-MSH), designed to act as a potent and selective melanocortin receptor agonist, particularly at MC3 and MC4. It is primarily researched for its unique ability to induce sexual arousal and enhance sexual function in both men and women without acting via direct hormonal or vascular mechanisms. PT-141 is supplied strictly for laboratory research use1,2,4.
Products will arrive in a lyophilized (powder) form for maximum stability
Tesamorelin 20mg
Summary Description: Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH), developed for the reduction of excess abdominal fat in HIV-associated lipodystrophy. It stimulates endogenous growth hormone (GH) secretion, thereby increasing insulin-like growth factor-1 (IGF-1) levels and promoting lipolysis. Tesamorelin selectively reduces visceral adipose tissue (VAT) without significant effects on subcutaneous fat and improves body image parameters. Its stability-enhancing N-terminal modification allows for effective subcutaneous administration, and it is FDA-approved for HIV-related lipodystrophy.
Products will arrive in a lyophilized (powder) form for maximum stability